Patents by Inventor Lawrence L. Kunz
Lawrence L. Kunz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170189098Abstract: Systems and methods for delivering electric fields to a target tissue of a patient for destruction of cancerous cells so as to elicit or induce a specific anti-cancerous cell immune response in the patient.Type: ApplicationFiled: November 15, 2016Publication date: July 6, 2017Inventors: Larry Azure, Charles E. Hill, Andrew L. Azure, Rafael Ponce, Lawrence L. Kunz
-
Patent number: 9526911Abstract: Systems and methods for delivering electric fields to a target tissue of a patient for destruction of cancerous cells so as to elicit or induce a specific anti-cancerous cell immune response in the patient.Type: GrantFiled: April 27, 2011Date of Patent: December 27, 2016Assignee: LAZURE SCIENTIFIC, INC.Inventors: Larry Azure, Charles E. Hill, Andrew L. Azure, Rafael Ponce, Lawrence L. Kunz
-
Publication number: 20120195951Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.Type: ApplicationFiled: April 13, 2012Publication date: August 2, 2012Inventors: Lawrence L. Kunz, Peter G. Anderson
-
Publication number: 20120191019Abstract: Methods and devices for applying high intensity focused ultrasound to modulate collagen in animal tissue (such as to disrupt collagen fibrils in a mammal, such as a human), particularly to enhance the aesthetic appearance of skin, and/or to otherwise improve skin conditions.Type: ApplicationFiled: July 22, 2011Publication date: July 26, 2012Applicant: Medicis Technologies CorporationInventors: Charles S. Desilets, Patrick J. Martin, Jens U. Quistgaard, Lawrence L. Kunz
-
Patent number: 8158670Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.Type: GrantFiled: January 4, 2007Date of Patent: April 17, 2012Assignee: Boston Scientific Scimed, Inc.Inventors: Lawrence L. Kunz, Peter G. Anderson
-
Patent number: 8097642Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.Type: GrantFiled: February 27, 2007Date of Patent: January 17, 2012Inventors: Lawrence L. Kunz, Peter G. Anderson
-
Publication number: 20110300221Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.Type: ApplicationFiled: August 15, 2011Publication date: December 8, 2011Inventors: Lawrence L. Kunz, Peter G. Anderson
-
Patent number: 8067022Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.Type: GrantFiled: July 20, 2001Date of Patent: November 29, 2011Assignee: Boston Scientific SciMed, Inc.Inventors: Lawrence L. Kunz, Peter G. Anderson
-
Publication number: 20090196931Abstract: Methods are provided for inhibiting or treating stenosis or restenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective amount of a therapeutic agent via a catheter. Also provided is a catheter adapted for administering a therapeutically effective amount of a therapeutic agent to a mammalian host for inhibiting or treating stenosis or restenosis.Type: ApplicationFiled: April 3, 2009Publication date: August 6, 2009Inventors: Lawrence L. Kunz, Peter G. Anderson
-
Publication number: 20040219223Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.Type: ApplicationFiled: June 2, 2004Publication date: November 4, 2004Applicant: Scimed Life Systems, Inc.Inventor: Lawrence L. Kunz
-
Patent number: 6720350Abstract: Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.Type: GrantFiled: December 27, 2002Date of Patent: April 13, 2004Assignee: SciMed Life Systems, Inc.Inventors: Lawrence L. Kunz, Richard A. Klein, John M. Reno
-
Patent number: 6663881Abstract: Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.Type: GrantFiled: December 18, 2001Date of Patent: December 16, 2003Assignee: NeoRx CorporationInventors: Lawrence L. Kunz, John M. Reno
-
Publication number: 20030203958Abstract: Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.Type: ApplicationFiled: December 27, 2002Publication date: October 30, 2003Applicant: NeoRx CorporationInventors: Lawrence L. Kunz, Richard A. Klein, John M. Reno
-
Patent number: 6599928Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.Type: GrantFiled: July 20, 2001Date of Patent: July 29, 2003Assignee: NeoRx CorporationInventors: Lawrence L. Kunz, Richard A. Klein
-
Patent number: 6569441Abstract: Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.Type: GrantFiled: November 27, 2001Date of Patent: May 27, 2003Assignee: NeoRx CorporationInventors: Lawrence L. Kunz, John M. Reno
-
Publication number: 20030083733Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.Type: ApplicationFiled: July 3, 2002Publication date: May 1, 2003Applicant: NeoRx CorporationInventor: Lawrence L. Kunz
-
Publication number: 20030039675Abstract: Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.Type: ApplicationFiled: November 27, 2001Publication date: February 27, 2003Applicant: Angiotech Pharmaceuticals, Inc.Inventors: Lawrence L. Kunz, John M. Reno
-
Patent number: 6515009Abstract: Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.Type: GrantFiled: February 15, 1995Date of Patent: February 4, 2003Assignee: NeoRx CorporationInventors: Lawrence L. Kunz, Richard A. Klein
-
Patent number: 6491938Abstract: Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.Type: GrantFiled: June 29, 2001Date of Patent: December 10, 2002Assignee: NeoRx CorporationInventors: Lawrence L. Kunz, John M. Reno
-
Publication number: 20020169138Abstract: Compositions for transporting a bioactive agent across a biological membrane include the bioactive agent, an oil, an oil-immiscible compound and a noncationic surface active agent. The compositions may deliver the bioactive agent through a chemical microporulation mechanism, which allows transfer of the agent across both cellular, intracellular organelle, and nuclear membranes. Compositions for nucleic acid delivery include nucleic acid, oil, oil-immiscible compound, noncationic surface active agent and essentially no cationic lipid, or include nucleic acid, oil, oil-immiscible compound and two noncationic surface active agents. The nucleic acid may be hydrophobically-modified, and be in combination with an oil, an oil-immiscible compound and at least one surface active agent. The compositions may be used for gene delivery to a cell, as well as delivery of other therapeutic agents.Type: ApplicationFiled: February 11, 2002Publication date: November 14, 2002Applicant: Southern Research InstituteInventors: Lawrence L. Kunz, Thomas R. Tice, Randell T. Libby, Christopher W. McDaniel